Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 445

1.

EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.

Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, Esteller M.

Cancer Res. 2005 Apr 1;65(7):2565-71.

2.

DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas.

Kunitz A, Wolter M, van den Boom J, Felsberg J, Tews B, Hahn M, Benner A, Sabel M, Lichter P, Reifenberger G, von Deimling A, Hartmann C.

Brain Pathol. 2007 Oct;17(4):363-70. Epub 2007 Jul 4.

PMID:
17610521
3.
4.

Frequent epigenetic inactivation of the SLIT2 gene in gliomas.

Dallol A, Krex D, Hesson L, Eng C, Maher ER, Latif F.

Oncogene. 2003 Jul 17;22(29):4611-6.

PMID:
12881718
5.

Coordinate downregulation of a novel imprinted transcript ITUP1 with PEG3 in glioma cell lines.

Maegawa S, Itaba N, Otsuka S, Kamitani H, Watanabe T, Tahimic CG, Nanba E, Oshimura M.

DNA Res. 2004 Feb 29;11(1):37-49.

PMID:
15141944
6.

Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas.

Mellai M, Piazzi A, Caldera V, Annovazzi L, Monzeglio O, Senetta R, Cassoni P, Schiffer D.

Biomed Res Int. 2013;2013:756302. doi: 10.1155/2013/756302. Epub 2013 Sep 3.

7.

RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.

Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F.

Oncogene. 2001 Nov 8;20(51):7573-7.

8.

EMP3 as a candidate tumor suppressor gene for solid tumors.

Fumoto S, Tanimoto K, Hiyama E, Noguchi T, Nishiyama M, Hiyama K.

Expert Opin Ther Targets. 2009 Jul;13(7):811-22. doi: 10.1517/14728220902988549. Review.

PMID:
19466912
9.

Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells.

Ropero S, Setien F, Espada J, Fraga MF, Herranz M, Asp J, Benassi MS, Franchi A, Patiño A, Ward LS, Bovee J, Cigudosa JC, Wim W, Esteller M.

Hum Mol Genet. 2004 Nov 15;13(22):2753-65. Epub 2004 Sep 22.

PMID:
15385438
10.

EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q.

Li KK, Pang JC, Chung NY, Ng YL, Chan NH, Zhou L, Poon WS, Ng HK.

Int J Cancer. 2007 Feb 15;120(4):947-50.

11.

A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation.

Carén H, Ejeskär K, Fransson S, Hesson L, Latif F, Sjöberg RM, Krona C, Martinsson T.

Mol Cancer. 2005 Mar 1;4(1):10.

12.

Epigenetic silencing of PEG3 gene expression in human glioma cell lines.

Maegawa S, Yoshioka H, Itaba N, Kubota N, Nishihara S, Shirayoshi Y, Nanba E, Oshimura M.

Mol Carcinog. 2001 May;31(1):1-9.

PMID:
11398192
13.

Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.

Hesson L, Bièche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, Latif F.

Oncogene. 2004 Mar 25;23(13):2408-19.

PMID:
14743209
14.

HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.

Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, Mori M, Sidransky D.

Mol Cancer Res. 2008 Jan;6(1):31-41. doi: 10.1158/1541-7786.MCR-07-0213.

15.

A microRNA DNA methylation signature for human cancer metastasis.

Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61. doi: 10.1073/pnas.0803055105. Epub 2008 Sep 3.

16.

LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation.

Pasini A, Iorio P, Bianchi E, Cerasoli S, Cremonini AM, Faedi M, Guarnieri C, Guiducci G, Riccioni L, Molinari C, Rengucci C, Calistri D, Giordano E.

Oncol Rep. 2012 Dec;28(6):2271-7. doi: 10.3892/or.2012.2047. Epub 2012 Sep 20.

PMID:
22992787
17.

An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma.

Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, Smith CA, Taylor MD, Rutka JT.

Cancer Res. 2008 Dec 1;68(23):9945-53. doi: 10.1158/0008-5472.CAN-08-2169.

18.

EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma.

Fumoto S, Hiyama K, Tanimoto K, Noguchi T, Hihara J, Hiyama E, Noguchi T, Nishiyama M.

Cancer Lett. 2009 Feb 8;274(1):25-32. doi: 10.1016/j.canlet.2008.08.021. Epub 2008 Sep 26.

PMID:
18823699
19.

Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.

Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC.

Cancer Res. 2002 Oct 15;62(20):5906-11.

20.

Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.

Carlsson E, Krohn K, Ovaska K, Lindberg P, Häyry V, Maliniemi P, Lintulahti A, Korja M, Kivisaari R, Hussein S, Sarna S, Niiranen K, Hautaniemi S, Haapasalo H, Ranki A.

Genes Chromosomes Cancer. 2013 Feb;52(2):191-201. doi: 10.1002/gcc.22019. Epub 2012 Oct 25.

PMID:
23097141

Supplemental Content

Support Center